The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20141569: Howard W. Lutnick; GFI Group Inc.
20141612: Stanford University; The Hospital Committee for the Livermore-Pleasanton Area
20141664: Google Inc.; Credit Karma, Inc.
20141667: TA XI L.P.; Genstar Capital Partners V, L.P.
20150009: Innospec Inc.; CSL Energy Opportunities Fund I, LP
20150018: Acorda Therapeutics, Inc.; Civitas Therapeutics, Inc.
20150019: Newell Rubbermaid Inc.; Jim Scott
20150023: STG IV, L.P.; McGraw Hill Financial, Inc.
20150030: Centerbridge Capital Partners II, L.P.; Capmark Financial Group Inc.
20141593: TCV VIII, L.P.; Shane Smith
20141655: Industrial Growth Partners IV, L.P.; Greenbriar Equity Fund II L.P.
20141665: Microsoft Corporation; Markus Persson
20141671: Melrose Industries PLC; Eclipse, Inc.
20150001: The Veritas Capital Fund IV, L.P.; EMCORE Corporation
20150025: Centerbridge Capital Partners II, L.P.; Bluestem Brands, Inc.
20150026: Capmark Financial Group Inc.; Bluestem Brands, Inc.
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.